Cassava Sciences, Inc. (SAVA) |
| 1.955 -0.035 (-1.76%) 03-16 15:59 |
| Open: | 1.97 |
| High: | 2.03 |
| Low: | 1.95 |
| Volume: | 258,479 |
| Market Cap: | 94(M) |
| PE Ratio: | -0.88 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.49 |
| Resistance 1: | 2.17 |
| Pivot price: | 1.93 |
| Support 1: | 1.64 |
| Support 2: | 1.36 |
| 52w High: | 4.98 |
| 52w Low: | 1.15 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Financials
| EPS | -2.220 |
| Book Value | 1.690 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.896 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -24.8 |
| Return on Equity (ttm) | -85.4 |
Company news
Thu, 02 Apr 2026
Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8% - Here's What Happened - MarketBeat
Tue, 10 Mar 2026
Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker - TipRanks
Tue, 10 Mar 2026
Cassava Sciences, Inc. will Change its Ticker to FLNA from SAVA - marketscreener.com
Tue, 10 Mar 2026
Filana Therapeutics (NASDAQ: FLNA) adopts new name and FLNA ticker - Stock Titan
Tue, 10 Mar 2026
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance
Thu, 19 Feb 2026
Cassava Sciences says US DOJ has closed investigation into company - Reuters
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
